Oruka Therapeutics, Inc.
91.50USD
-2.8100 (-2.98%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 0.0 | 0.0 | — | — | 0.0 | 0.0 |
| Q1 | 0.0 | 0.0 | 0.0 | — | — | — |
| Q2 | 0.0 | 0.0 | 0.0 | — | — | — |
| Q3 | 0.0 | 0.0 | — | — | 0.0 | — |
| Q4 | 0.0 | 0.0 | — | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.230 | -.123 | — | — | -2.37 | -2.86 |
| Q1 | -.077 | -.030 | -.047 | -.400 | — | — |
| Q2 | -.073 | -.033 | -.515 | -.460 | — | — |
| Q3 | -.053 | -.033 | -.487 | — | -.618 | — |
| Q4 | -.027 |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.027 |
| — |
| — |
| -.663 |
| — |